INBX news & sentiment — Inhibrx Biosciences, Inc.

MAY 13·BioPharma APACHigh

Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer

Inhibrx Biosciences announced positive interim Phase 2 results for INBRX-106 combined with pembrolizumab in head and neck cancer, showing a 44% confirmed objective response rate and deeper tumor reductions compared to pembrolizumab alone. The study demonstrated robust T-cell expansion and a manageable safety profile. The company plans to advance to Phase 3 and explore broader indications for OX40 agonism.

OCT 24·Benzinga

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? - Inhibrx Biosciences ( NASDAQ:INBX )

Inhibrx Biosciences Inc. ( NASDAQ:INBX ) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90. Check out the current price of INBX stock here. According to Benzinga Pro data, the stock closed regular trading at $28.36, down 10.03%.

AUG 13·Motley Fool

Inhibrx Biosciences Beats Earnings

Inhibrx Biosciences ( NASDAQ:INBX ) , a clinical-stage biotechnology company specializing in novel biologic therapies, released its second quarter 2025 earnings on August 13, 2025. The most significant news from the release includes a narrower-than-expected GAAP net loss per share and GAAP ...

$INBX

Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? - Inhibrx Biosciences ( NASDAQ:INBX )

Inhibrx Biosciences Beats Earnings

News on $INBX